company background image
AMLX

Amylyx Pharmaceuticals NasdaqGS:AMLX Stock Report

Last Price

US$28.18

Market Cap

US$1.6b

7D

-8.9%

1Y

n/a

Updated

26 Sep, 2022

Data

Company Financials +
AMLX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

AMLX Stock Overview

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

Amylyx Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Amylyx Pharmaceuticals
Historical stock prices
Current Share PriceUS$28.18
52 Week HighUS$33.41
52 Week LowUS$6.51
Beta0
1 Month Change7.11%
3 Month Change43.19%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO55.95%

Recent News & Updates

Sep 08

Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing

Amylyx Pharmaceutical (NASDAQ:AMLX) is trading 81% higher premarket after a panel of experts to the U.S. Food and Drug Administration voted in favor to recommend approval of the drug, AMX0035, to treat neurodegenerative disease amyotrophic lateral sclerosis (ALS). If gains hold, the stock is set to reverse its YTD losses. In a rare second meeting, the FDA's panel voted 7 in favor and 2 against for the drug. The advisory committee's nod comes after the panel in March rejected the drug due to issues with trial data. The FDA often follows the advisory committee's recommendations, though it is not obligated to. A decision by the FDA is expected by Sept. 29. Shares of Reata Pharmaceuticals (RETA) and Ardelyx (ARDX), fellow clinical-stage biopharma companies that face their own upcoming AdCom meetings, are up ~10% and 2.5% higher, respectively. Citi research analyst Neena Bitritto-Garg thinks the approval is now "very highly likely", particularly due to the political pressure to approve new therapies for ALS, raises price target to $48 from $35.

Sep 02

Amylyx plunges 28% after FDA briefing documents on ALS drug

Amylyx Pharmaceuticals (NASDAQ:AMLX), a company focused on neurodegenerative diseases, lost ~28% in value on Friday after the FDA posted briefing documents ahead of an advisory committee meeting scheduled for next week on its candidate for amyotrophic lateral sclerosis AMX0035. The shares of Reata Pharmaceuticals (RETA), a developer focused on another neurological disease called Friedreich’s ataxia, have also come under pressure in reaction. Sep. 07 AdCom meeting will be the second review the FDA’s independent experts will conduct on the drug after a negative vote in March. However, the FDA extended the review period of AMLX’s new drug application (NDA) for AMX0035 by three months to analyze additional data extending the PDUFA date to Seep. 29 from the original date of Jun. 29. This is a developing story. Check back for more updates.

Aug 29
We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

AMLXUS PharmaceuticalsUS Market
7D-8.9%-1.9%-5.2%
1Yn/a2.9%-23.0%

Return vs Industry: Insufficient data to determine how AMLX performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how AMLX performed against the US Market.

Price Volatility

Is AMLX's price volatile compared to industry and market?
AMLX volatility
AMLX Average Weekly Movement18.5%
Pharmaceuticals Industry Average Movement11.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: AMLX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: AMLX's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2013226Josh Cohenhttps://amylyx.com

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company’s product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases.

Amylyx Pharmaceuticals, Inc. Fundamentals Summary

How do Amylyx Pharmaceuticals's earnings and revenue compare to its market cap?
AMLX fundamental statistics
Market CapUS$1.63b
Earnings (TTM)-US$153.40m
Revenue (TTM)US$285.00k

5,798x

P/S Ratio

-10.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AMLX income statement (TTM)
RevenueUS$285.00k
Cost of RevenueUS$71.97m
Gross Profit-US$71.68m
Other ExpensesUS$81.72m
Earnings-US$153.40m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.62
Gross Margin-25,152.63%
Net Profit Margin-53,824.91%
Debt/Equity Ratio0%

How did AMLX perform over the long term?

See historical performance and comparison